FDA opens door to emer­gency use of con­va­les­cent plas­ma from re­cov­ered Covid-19 pa­tients

One po­ten­tial treat­ment for Covid-19, known as con­va­les­cent plas­ma, may be de­rived from pa­tients who have al­ready re­cov­ered from the dis­ease, and the FDA said …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.